EGFR and non-small cell lung carcinoma: For example, in advanced stage NSCLC patients, ctDNA has been successfully used to evaluate the development of EGFR exon 20 p.T790M resistance point mutation after treatment with first‐ or second‐generation EGFR tyrosine kinase inhibitors (TKIs) [49].